Semaglutide, tirzepatide, and other GLP-1 receptor agonists are the cornerstone pharmacotherapy for chronic weight management in 2026. This category covers FDA-approved brand options (Wegovy, the Wegovy pill, Zepbound and Foundayo), compounded telehealth pathways, and investigational molecules such as retatrutide.
6 peptides coveredv4.1 methodologyAll 50 states + DC
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.
See the full provider directory for profiles, dated prices and scores.
Editorial team
Researched by Dr. Parmis (Medical Researcher, Western University of Health Sciences); medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC).